Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
US9382286B2 · kind B2 · utility
0Cited by
1References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 4, 2013 |
| Grant date | Jul 5, 2016 |
| Priority date | — |
| Expiry date | Dec 4, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.